Key Insights

Highlights

Success Rate

91% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

3.8%

2 terminated out of 52 trials

Success Rate

90.9%

+4.4% vs benchmark

Late-Stage Pipeline

2%

1 trials in Phase 3/4

Results Transparency

40%

8 of 20 completed with results

Key Signals

8 with results91% success

Data Visualizations

Phase Distribution

46Total
Not Applicable (14)
P 1 (8)
P 2 (23)
P 3 (1)

Trial Status

Completed20
Recruiting13
Active Not Recruiting7
Not Yet Recruiting5
Unknown4
Terminated2

Trial Success Rate

90.9%

Benchmark: 86.5%

Based on 20 completed trials

Clinical Trials (52)

Showing 20 of 20 trials
NCT02012699Recruiting

Integrated Cancer Repository for Cancer Research

NCT05946993Not ApplicableActive Not Recruiting

Linking In With Advice and Supports for Men Impacted by Metastatic Cancer

NCT07378670Not ApplicableRecruitingPrimary

DEfeating PEnile CAncer-2

NCT07518979Phase 2Not Yet RecruitingPrimary

EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer

NCT04708470Phase 1Active Not Recruiting

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

NCT07497919Phase 2Not Yet RecruitingPrimary

A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer

NCT05842031SuspendedPrimary

Assessment of Patient Experience and Needs for Patients Undergoing Invasive Inguinal Lymph Node Procedures for Penile Cancer

NCT05686226Phase 2Recruiting

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

NCT05639972Phase 1Recruiting

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

NCT07384416Phase 2Not Yet RecruitingPrimary

Single-Arm Trial of QL1706, Lenvatinib, and Nab-Paclitaxel for Advanced Refractory Penile Cancer

NCT03333616Phase 2Active Not Recruiting

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

NCT05264337Recruiting

Lymphedema After Urologic Surgery

NCT03391479Phase 2Active Not RecruitingPrimary

A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy

NCT06353906Phase 2Recruiting

Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer

NCT06582849Not ApplicableCompleted

Enhanced Assistance During Radiotherapy for Unmet Essential Needs

NCT06683846Phase 2Recruiting

Ivonescimab in the Treatment of Multiple Advanced Tumors

NCT07101822Phase 2Not Yet RecruitingPrimary

A PHASE II, RANDOMIZED STUDY TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT PENILE CANCER

NCT07054307Phase 1Not Yet RecruitingPrimary

MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma

NCT02817958Phase 2Active Not RecruitingPrimary

Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis

NCT04231981Phase 2CompletedPrimary

Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)

Scroll to load more

Research Network

Activity Timeline